https://www.medscape.com/viewarticle/995877
0
0
8/26/23 at 9:55pm
Organization
Medscape
40 words
0
Comments
New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease.
You are the first to view
Create an account
or login to join the discussion